{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-Mediated+Rejection+%28AMR%29", "query": { "condition": "Antibody-Mediated Rejection (AMR)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibody-Mediated+Rejection+%28AMR%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T15:46:15.109Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03744910", "title": "Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Antibody-mediated Rejection" ], "interventions": [ { "name": "Clazakizumab", "type": "BIOLOGICAL" }, { "name": "Physiologic saline solution", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 194, "start_date": "2019-10-14", "completion_date": "2024-04-08", "has_results": true, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03744910" }, { "nct_id": "NCT02547220", "title": "A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Antibody-Mediated Rejection (AMR)" ], "interventions": [ { "name": "Cinryze®", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2016-05-20", "completion_date": "2019-05-31", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 29, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02547220" }, { "nct_id": "NCT07613359", "title": "A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antibody-Mediated Rejection (AMR)" ], "interventions": [ { "name": "Mezagitamab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 36, "start_date": "2026-09-01", "completion_date": "2029-01-15", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07613359" }, { "nct_id": "NCT00670774", "title": "Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Transplant" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mark Stegall", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2008-03", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00670774" }, { "nct_id": "NCT07444489", "title": "A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Antibody-mediated Rejection", "Microvascular Inflammation" ], "interventions": [ { "name": "Felzartamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 201, "start_date": "2026-04-16", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 13, "location_summary": "Los Angeles, California • San Francisco, California • Rochester, Minnesota + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444489" }, { "nct_id": "NCT05156710", "title": "BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant Rejection" ], "interventions": [ { "name": "BIVV020 (SAR445088)", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIg)", "type": "DRUG" }, { "name": "Rituximab or biosimilar", "type": "DRUG" }, { "name": "Antithymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2022-06-09", "completion_date": "2026-10-20", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156710" }, { "nct_id": "NCT06685757", "title": "A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Antibody-mediated Rejection" ], "interventions": [ { "name": "Felzartamab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 132, "start_date": "2024-12-03", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 26, "location_summary": "Los Angeles, California • Orange, California • San Bernardino, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06685757" }, { "nct_id": "NCT06503731", "title": "A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antibody-mediated Rejection" ], "interventions": [ { "name": "Efgartigimod PH20 SC - prefilled syringe", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo PH20 SC - prefilled syringe", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 33, "start_date": "2024-08-30", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06503731" }, { "nct_id": "NCT01399593", "title": "Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Antibody Mediated Rejection" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2011-11-02", "completion_date": "2015-11-13", "has_results": true, "last_update_posted_date": "2017-10-03", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 17, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01399593" }, { "nct_id": "NCT06990711", "title": "A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Antibody Mediated Rejection of Lung Transplant" ], "interventions": [ { "name": "Siltuximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-11-06", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-30T15:46:15.109Z", "location_count": 2, "location_summary": "St Louis, Missouri • Saint Lake City, Utah", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Saint Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06990711" } ] }